Full-Time

Associate Director

Medical Safety Science, Safety Scientist

Updated on 9/4/2026

Mirum Pharmaceuticals

Mirum Pharmaceuticals

201-500 employees

ASBT inhibitors for rare liver diseases

Compensation Overview

$215k - $230k/yr

Foster City, CA, USA

Hybrid

The posting is marked hybrid.

Bachelor's, Master's, PharmD

Category
Biology & Biotech
Required Skills
Medical Terminology

Get referred to Mirum Pharmaceuticals

See people who can refer or advise you

Requirements
  • A bachelor's degree in a scientific discipline is required.
  • A minimum of 7 years of pharmaceutical or contract research organization experience in a clinical trial or post-market setting is required, including 5 years in a drug safety and pharmacovigilance role specifically as a Safety Scientist.
  • Experience in safety surveillance activities, including signal detection activities, is required.
  • Experience authoring aggregate reports such as Development Safety Update Reports, Periodic Safety Update Reports or Periodic Benefit-Risk Evaluation Reports, and Periodic Adverse Drug Experience Reports is required.
  • Experience reviewing adverse event and medical history coding is required.
  • Experience serving as a subject matter expert for Safety Science in audits and inspections is required.
  • Strong interpersonal and written and oral communication skills are required.
  • Attention to detail, critical thinking, and organizational skills are required.
  • Ability to assess data and understand medical and safety implications is required.
  • Ability to work within a matrix environment and communicate effectively across organizational levels is required.
  • Ability to work independently and collaboratively is required.
Responsibilities
  • Conduct sponsor oversight from a safety science perspective and assess individual case safety reports in post-marketing and clinical trial settings.
  • Generate outputs from the safety database for aggregate reports and ad hoc requests.
  • Perform coding reviews of adverse events and medical history in the clinical database for Mirum products and studies.
  • Facilitate and author aggregate safety reports, including Development Safety Update Reports, Periodic Adverse Drug Experience Reports, and Periodic Safety Update Reports.
  • Represent Medical Safety Science in assigned clinical study team meetings.
  • Support the Senior Director of Medical Safety in Safety Adjudication Meetings.
  • Review and develop Medical Safety Science standard operating procedures and work instructions.
  • Support safety surveillance and pharmacovigilance activities, including signal detection and validation, Safety Review Team meetings, and Global Safety Committee meetings.
  • Monitor and track signals; schedule Safety Review Team and Global Safety Committee meetings; and review meeting slides and signal detection reports.
  • Review and revise medical safety science sections in study protocols, informed consent forms, and periodic reports.
  • Review safety-related documents such as Joint Operating Guidelines and monthly reports.
  • Provide vendor training for new products and studies.
  • Maintain expectedness trackers for reference safety information and product labels.
  • Maintain safety templates, including targeted questionnaires and protocol safety reporting language.
  • Review and revise safety management plans, safety data exchange agreements, applicable standard operating procedures, and related forms from a Medical Safety Science perspective.
  • Work closely with Medical Safety Operations to provide scientific input as needed.
  • Review and assess literature search results.
  • Create procedures and processes for Safety Science activities to support pharmacovigilance inspection readiness and participate in audits and inspections as the Safety Science subject matter expert.
Desired Qualifications
  • A Registered Nurse, Master of Science, or Doctor of Pharmacy degree is highly desired; coursework in clinical research is preferred.
  • Understanding of medical terminology and ability to summarize medical information is preferred.
  • Master of Science or Doctor of Pharmacy degree is highly desired.
  • MSSO training and UMC training are preferred.
  • Safety database and data entry experience are preferred, including understanding safety database structures and familiarity with data retrieval tools.
Mirum Pharmaceuticals

Mirum Pharmaceuticals

View

Mirum Pharmaceuticals develops and commercializes therapies for rare liver diseases. Its lead drug LIVMARLI (maralixibat) is an oral ASBT inhibitor that lowers bile acid buildup to relieve itching in cholestatic conditions such as Alagille syndrome, and the company is pursuing LIVMARLI for additional rare liver diseases, with volixibat as another ASBT inhibitor in its pipeline. The company differentiates itself by focusing on rare pediatric and adult cholestatic diseases and building dedicated commercialization infrastructure in the U.S. and other major markets, including partnerships with physicians, payers, and patient groups to improve patient access. Mirum’s goal is to bring effective therapies to patients with rare bile-duct and liver disorders, expand LIVMARLI indications, and establish a sustainable market presence in key markets.

Company Size

201-500

Company Stage

IPO

Headquarters

Foster City, California

Founded

2018

Get referred to Mirum Pharmaceuticals

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Q2 2026 net product sales reached $176.2 million, and guidance rose to $700 million.
  • Rob Myers starts September 21, 2026, strengthening hepatology leadership before key readouts.
  • Volixibat, brelovitug, and zilurgisertib create multiple catalysts through first-half 2027.

What critics are saying

  • FDA recommended another volixibat Phase 3 on August 5, 2026, delaying PSC filing.
  • If LIVMARLI growth slows, Mirum loses the cash engine funding its pipeline.
  • Zilurgisertib’s September 26, 2026 PDUFA denial would crush sentiment and financing flexibility.

What makes Mirum Pharmaceuticals unique

  • LIVMARLI dominates rare pediatric cholestatic disease with expanding PFIC and biliary atresia labels.
  • Mirum combines commercialization strength with late-stage hepatology pipeline breadth across PSC, HDV, and FOP.
  • Exclusive zilurgisertib rights from Incyte add a near-term rare-disease launch platform.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Hybrid Work Options

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

-1%

2 year growth

0%
Yahoo Finance
Sep 8th, 2026
Mirum Pharmaceuticals appoints Dr Rob Myers as chief medical officer

Mirum Pharmaceuticals has appointed Dr Rob Myers as chief medical officer, effective 21 September 2026. Dr Myers will lead the company's global medical and clinical development functions. Dr Myers brings over 20 years of experience in drug development, with particular expertise in hepatology. He joins from OrsoBio, where he served as chief medical officer and head of development. Previously, he held senior leadership positions at Gilead Sciences, overseeing clinical development programmes across liver fibrosis, cholestatic liver diseases, and gastrointestinal inflammation. Dr Myers has published more than 200 peer-reviewed papers and has contributed to advancing understanding of primary sclerosing cholangitis. He holds an MD from Western University and a master's degree in epidemiology from the University of Calgary.

CNBC TV18
Aug 20th, 2026
US FDA approves Regeneron's rare bone disorder drug.

US FDA approves Regeneron's rare bone disorder drug. Regeneron's Pasatru has received US FDA approval for adults with FOP after clinical trials showed a significant reduction in abnormal bone formation. By Reuters August 20, 2026, 8:59:40 AM IST (Published) The US FDA on Wednesday (August 19) approved Regeneron's drug for a rare genetic disorder after it significantly reduced abnormal bone formation in certain soft tissues. New York-based Regeneron's shares rose 4%. The drug, garetosmab, branded as Pasatru, was approved to treat adults with fibrodysplasia ossificans progressiva (FOP) - a condition in which muscle, tendon and ligament tissue gradually turns into bone, leading to a "second skeleton" that causes progressive loss of mobility and reduced life expectancy. In a 56-week trial involving 63 participants, Pasatru reduced the development of new bone abnormalities by 94% in patients treated with a 3 mg per kg dose and by 90% in those given a 10 mg per kg dose, compared with a placebo. The drug works by blocking Activin A, a protein involved in triggering abnormal bone growth in patients with FOP. Susan Rhee, a member of Regeneron's clinical team, told Reuters last week that the company plans to start a trial for children later this year. The drug will compete with French drugmaker Ipsen's oral treatment Sohonos, which in 2023 became the only other treatment approved by the US Food and Drug Administration. Incyte and partner Mirum Pharma, as well as privately held Ashibio, are also developing treatments for the condition. In 2020, Regeneron paused dosing in a mid-stage trial of the drug after five patient deaths, ultimately discontinuing the study and working with global regulators to design the late-stage trial, according to the company. The condition affects roughly 1 in 2 million people worldwide, with around 800 to 900 active diagnosed cases globally, according to data from the National Institutes of Health.

Yahoo Finance
Aug 6th, 2026
FDA requests Phase 3 trial for Mirum's Volixibat, delaying NDA until H1 2027 — MIRM stock crashes 15%

Mirum Pharmaceuticals shares plunged 15% on Thursday after the FDA recommended an additional Phase 3 study for its liver disease candidate Volixibat, potentially delaying the new drug application until the first half of 2027. Citizens lowered its price target to $137 from $146 whilst maintaining an Outperform rating. The regulatory setback overshadowed strong second-quarter results. Mirum reported revenue of $176.2 million, beating analysts' estimates of $167.3 million. The company raised its full-year net product sales guidance to $680 million to $700 million, from $660 million to $680 million. Mirum ended the quarter with $561.3 million in cash and equivalents. Volixibat has already received FDA Breakthrough Therapy and Orphan Drug designations.

Yahoo Finance
Aug 6th, 2026
Mirum raises 2026 guidance to $700M, delays PSC drug filing amid FDA review

Mirum Pharmaceuticals raised its full-year 2026 net product sales guidance to $680 million to $700 million, citing growth in Alagille syndrome and expanding adult PFIC diagnosis. The company secured $690 million through a convertible note offering, improving its capital structure whilst settling 75% of 2029 notes. The firm identified a significant opportunity in adult PFIC, estimating at least 2,000 addressable patients each in the US and Europe. Commercial operations achieved a high-50s percent cash contribution margin, representing a 5 percentage point year-over-year improvement. Mirum delayed its volixibat PSC NDA submission due to alignment issues with FDA reviewers but received Breakthrough Therapy Designation. The company targets a first-half 2027 NDA submission for PSC and anticipates Phase III PBC results in Q1 2027.

Yahoo Finance
Aug 6th, 2026
Mirum Pharmaceuticals' Q2 revenue hits $176M, up 38% year-on-year despite widened loss

Mirum Pharmaceuticals reported revenue of $176.24 million for the quarter ended June 2026, up 37.9% year-over-year. The figure exceeded the consensus estimate of $164.76 million by 6.97%. The company posted a loss of $0.80 per share, compared to $0.12 a year ago, slightly missing the estimated loss of $0.77 per share. Product sales showed strong performance across categories. Livmarli generated $128.72 million, surpassing the $119.6 million analyst estimate. Bile acid medicines brought in $47.52 million, also beating expectations of $45.64 million. Despite beating revenue estimates, Mirum's shares fell 18.7% over the past month, underperforming the S&P 500's 3.5% gain.